Edition:
India

Almirall SA (ALM.MC)

ALM.MC on Madrid SE C.A.T.S.

9.57EUR
30 Sep 2020
Change (% chg)

€0.23 (+2.52%)
Prev Close
€9.34
Open
€9.29
Day's High
€9.61
Day's Low
€9.25
Volume
366,856
Avg. Vol
484,633
52-wk High
€18.50
52-wk Low
€8.80

Latest Key Developments (Source: Significant Developments)

Almirall To Run Share Capital Increase As Instrument Of Flexible Dividend Program
Monday, 7 Sep 2020 

Sept 7 (Reuters) - Almirall SA ::TO RUN SHARE CAPITAL INCREASE AS INSTRUMENT OF FLEXIBLE DIVIDEND PROGRAM.SAYS SCRIP DIVIDEND OF 0.198 EUROS GROSS/RIGHT.  Full Article

Almirall H1 Net Profit Down At 42.4 Million Euros YoY
Monday, 27 Jul 2020 

July 27 (Reuters) - Almirall SA ::H1 NET PROFIT 42.4 MILLION EUROS VERSUS PROFIT 61.9 MILLION EUROS YEAR AGO.H1 NET SALES 426.0 MILLION EUROS VERSUS 432.6 MILLION EUROS YEAR AGO.H1 EBITDA 137.2 MILLION EUROS VS 166.2 MILLION EUROS YEAR AGO.  Full Article

Almirall Revises FY 2020 Guidance To Include COVID-19 Impact
Monday, 27 Jul 2020 

July 27 (Reuters) - Almirall SA ::THE GROUP'S PRODUCTION ACTIVITIES HAVE NOT BEEN DISRUPTED DURING PANDEMIC AND THE SUPPLY OF MEDICINES HAS BEEN CARRIED OUT AS NORMAL.DESPITE NOT DISRUPTING PRODUCTION ACTIVITY, GROUP'S SALES HAVE BEEN NEGATIVELY IMPACTED AS RESULT OF GLOBAL ECONOMY, AS WELL AS BY RESTRICTION OF PEOPLE MOBILITY.SAYS WITH RESPECT TO VALUATION OF INVENTORIES, THERE HAS BEEN NO PROVISION FOR SLOW ROTATION OR EXPIRATION RELATED TO COVID-19.FROM A LIQUIDITY POINT OF VIEW, COVID-19 HAS NOT HAD A SIGNIFICANT IMPACT ON THE GROUP.FY 2020 GUIDANCE REVISED TO INCLUDE COVID-19 IMPACT.SEES 2020 NET SALES OF LOW TO MID-SINGLE-DIGIT DECLINE, REVISED FROM LOW TO MID-SINGLE-DIGIT GROWTH .SEES 2020 EBITDA OF BETWEEN 230-250 MILLION EUROS, REVISED FROM BETWEEN 260-280 MILLION EUROS.  Full Article

Almirall Signs Syndicated Financing Contract For 275 Mln Euros For An Initial Period Of 3 Yrs
Monday, 20 Jul 2020 

July 20 (Reuters) - Almirall SA ::SIGNS SYNDICATED FINANCING CONTRACT FOR 275.0 MILLION EUROS, FOR A PERIOD OF INITIAL 3 YEARS WITH POSSIBILITY OF EXTENSION FOR 1 ADDITIONAL YEAR.SAYS BBVA ACTED AS OPERATION COORDINATOR AND FINANCING CONTRACT REPLACES ONE PREVIOUSLY SIGNED WITH A MATURITY DATE OF FEBRUARY 2021.FINANCING CONTRACT INTENDED FOR GENERAL CORPORATE USE.  Full Article

Almirall Q1 Net Profit Up At 48.6 Mln Euros YoY, Maintains Guidance
Monday, 11 May 2020 

May 11 (Reuters) - Almirall SA ::Q1 REVENUE 247.3 MILLION EUROS VERSUS 232.2 MILLION EUROS YEAR AGO.Q1 EBITDA 88.3 MILLION EUROS VERSUS 80.2 MILLION EUROS YEAR AGO.Q1 NET PROFIT AT 48.6 MILLION EUROS VERSUS 29.9 MILLION EUROS YEAR AGO.Q1 NORMALIZED NET PROFIT 48.9 MILLION EUROS VERSUS 32.6 MILLION EUROS YEAR AGO.SAYS GUIDANCE MAINTAINED.SEES NET SALES LOW TO MID SINGLE-DIGIT GROWTH, EBITDA BETWEEN €260 - €280 MILLION, SUBJECT TO PROGRESSIVE NORMALISATION OF HEALTHCARE SYSTEMS BY END-Q2.SAYS EXPECT COVID-19 IMPACT IN Q2 ESPECIALLY IN U.S..SAYS 100% OF MANUFACTURING SITES OPERATING AT FULL CAPACITY.Q1 R&D 21.3 MLN EUROS VS 21.7 MLN EUROS YR AGO.SAYS RESEARCH AND DEVELOPMENT SPEND FLAT DUE TO LOWER PHASE IV STUDIES, IMPACTED BY COVID-19.  Full Article

Almirall Announces Pipeline Update
Monday, 28 Oct 2019 

Oct 28 (Reuters) - Almirall SA ::EXPECTS TO REPORT TOPLINE FINDINGS FROM THE 16-WEEK INDUCTION PERIOD UNDER LEBRIKIZUMAB PROGRAM IN H1 2021.FIRST NATIONAL PHASE APPROVAL FOR TERBINAFINE IS ESTIMATED IN 2020 OR EARLY 2021 IN EUROPE.FIRST NATIONAL PHASE APPROVAL FOR FINASTERIDE IS ESTIMATED IN 2020 OR EARLY 2021 IN EUROPE.EXPECTS TO SUBMIT NDA IN US AND MMA IN EUROPE FOR ALM14789 IN ACTINIC KERATOSIS IN Q1 2021 AND Q2 2021.  Full Article

Almirall Appoints Mike McClellan As New CFO
Monday, 16 Sep 2019 

Sept 16 (Reuters) - Almirall SA ::SAYS MIKE MCCLELLAN WILL JOIN AS NEW CFO ON NOVEMBER 11, 2019.SAYS DAVID NIETO DECIDED TO STEP DOWN FROM HIS ROLE AS CFO.  Full Article

Almirall H1 Net Profit Up At 61.9 Mln Euros YoY
Monday, 29 Jul 2019 

July 29 (Reuters) - Almirall SA ::H1 NET PROFIT 61.9 MILLION EUROS VERSUS 52.0 MILLION EUROS YEAR AGO.H1 NET SALES 432.6 MILLION EUROS VERSUS 367.4 MILLION EUROS YEAR AGO.2019 FULL YEAR GUIDANCE UPGRADED.SEES 2019 TOTAL REVENUES AT LOW DOUBLE-DIGIT GROWTH.UPGRADES EBITDA GUIDANCE TO 300-310 MILLION EUROS FOR THE FULL YEAR (FROM 290-300 MILLION EUROS PREVIOUSLY).H1 EBITDA 166.2 MILLION EUROS VERSUS 105.5 MILLION EUROS YEAR AGO.  Full Article

Almirall Announces Re-Designation 250 Mln Euro Senior Unsecured Conditionally Convertible Bonds Due 2021 As Convertible And/Or Exchangeable Bonds
Monday, 17 Jun 2019 

June 17 (Reuters) - Almirall SA ::ANNOUNCES RE-DESIGNATION 250 MILLION EURO SENIOR UNSECURED CONDITIONALLY CONVERTIBLE BONDS DUE 2021 AS CONVERTIBLE AND/OR EXCHANGEABLE BONDS.NEW ISSUE REQUIREMENTS HAVE BEEN SATISFIED AND BONDS HAVE BEEN RE-DESIGNATED WITH EFFECT FROM JUNE 25 2019.  Full Article

Almirall To Make Decision Regarding Exercise Of Its Lebrikizumab Option By Mid-Year
Monday, 3 Jun 2019 

June 3 (Reuters) - Almirall SA ::TO MAKE DECISION REGARDING EXERCISE OF OPTION TO EXCLUSIVELY LICENSE RIGHTS TO DEVELOP AND COMMERCIALIZE LEBRIKIZUMAB IN EUROPE BY MID-YEAR.IF ALMIRALL ELECTS TO EXERCISE ITS OPTION, COMPANY WILL PAY DERMIRA AN OPTION EXERCISE FEE OF $50 MILLION.  Full Article

UPDATE 1-Spain's Almirall said coronavirus to hit 2020 sales, earnings

BARCELONA, July 27 Spanish pharmaceutical firm Almirall lowered its 2020 outlook on Monday, forecasting a decrease in net sales and core earnings after the coronavirus pandemic hit its dermatology business, bringing net profit down 31.5% in the first semester.